Asset profile
Evogliptin · Suganon
Small molecule
Evidence outlook · lead readout
NCT04170998 · Type 2 Diabetes
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT04170998: This was a randomized, quadruple-blind, placebo-controlled trial (n=283) adding evogliptin or placebo onto metformin plus dapagliflozin. The primary endpoint, HbA1c change at 24 weeks, was clearly met: evogliptin reduced HbA1c significantly more than placebo (p<0.0001), with the benefit maintained at 52 weeks.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
79 competitors in this universe: 19 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 33 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Evogliptin (Suganon): this drug | Phase 3 | Small molecule | DPP-4 | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Linagliptin (Tradjenta) | Approved | Small molecule | DPP-4 | ||
| Saxagliptin (Onglyza) | Approved | Small molecule | DPP-4 | ||
| Sitagliptin (Januvia) | Approved | Small molecule | DPP-4 | ||
| Anagliptin (Suiny) | Phase 3 | Small molecule | DPP-4 | ||
| DBPR108 | Phase 3 | Small molecule | DPP-4 | ||
| Gemigliptin (Zemiglo) | Phase 3 | Small molecule | DPP-4 | ||
| Gosogliptin | Phase 3 | Small molecule | DPP-4 | ||
| Henagliflozin | Phase 3 | Small molecule | Sodium-glucose cotransporter 2 (SGLT2), DPP-4 | ||
| MP-513 | Phase 3 | Small molecule | DPP-4 | ||
| Omarigliptin (Marizev) | Phase 3 | Small molecule | DPP-4 | ||
| SP2086 | Phase 3 | Small molecule | DPP-4 | ||
| SYR-472 | Phase 3 | Small molecule | DPP-4 | ||
| Teneligliptin (Tenelia) | Phase 3 | Small molecule | DPP-4 | ||
| Trelagliptin (Zafatek) | Phase 3 | Small molecule | DPP-4 |
…and 64 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
13 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.